BTK-话题@MedSci

#BTK#

73篇内容 | 1034人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2189404, encodeId=3c7a2189404ff, content=<a href='/topic/show?id=bde45355068' target=_blank style='color:#2F92EE;'>#慢性淋巴细胞白血病#</a> <a href='/topic/show?id=6bce3e7106' target=_blank style='color:#2F92EE;'>#BTK#</a> <a href='/topic/show?id=5be526941ee' target=_blank style='color:#2F92EE;'>#依鲁替尼#</a> <a href='/topic/show?id=42e31115585a' target=_blank style='color:#2F92EE;'>#NX-2127#</a>, objectTitle=Science：下一代BTK降解剂有望治疗慢性淋巴细胞白血病, objectType=article, longId=814168, objectId=efea8141686a, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/bioon-com/20240221/1708517102686_2185383.png, objectUrl=/article/show_article.do?id=efea8141686a, replyNumber=0, likeNumber=10, createdTime=2024-02-26, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=0, avatar=, status=0, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=null, followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1539131, encodeId=97591539131b5, content=<a href='/topic/show?id=6bce3e7106' target=_blank style='color:#2F92EE;'>#BTK#</a>, objectTitle=BJD：天疱疮治疗新靶点：BTK抑制剂, objectType=article, longId=295216, objectId=435a29521617, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=435a29521617, replyNumber=0, likeNumber=36, createdTime=2022-02-08, rootId=0, userName=fengting7, userId=61d813108447, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=435a29521617, moduleTitle=BJD：天疱疮治疗新靶点：BTK抑制剂, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=435a29521617)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539130, encodeId=11c0153913022, content=<a href='/topic/show?id=6bce3e7106' target=_blank style='color:#2F92EE;'>#BTK#</a>, objectTitle=Clin Cancer Res：采用新型BTK抑制剂Zanubrutinib治疗复发/难治性边缘区淋巴瘤, objectType=article, longId=221654, objectId=607c22165460, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=607c22165460, replyNumber=0, likeNumber=39, createdTime=2021-12-08, rootId=0, userName=fengting7, userId=61d813108447, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=607c22165460, moduleTitle=Clin Cancer Res：采用新型BTK抑制剂Zanubrutinib治疗复发/难治性边缘区淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=607c22165460)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539129, encodeId=f554153912954, content=<a href='/topic/show?id=6bce3e7106' target=_blank style='color:#2F92EE;'>#BTK#</a>, objectTitle=Lancet Neurol：口服脑穿透性BTK抑制剂托莱布替尼治疗复发性多发性硬化症的安全性和有效性？, objectType=article, longId=219170, objectId=015e2191e0a9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=015e2191e0a9, replyNumber=0, likeNumber=28, createdTime=2021-10-25, rootId=0, userName=fengting7, userId=61d813108447, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=015e2191e0a9, moduleTitle=Lancet Neurol：口服脑穿透性BTK抑制剂托莱布替尼治疗复发性多发性硬化症的安全性和有效性？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=015e2191e0a9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539128, encodeId=c69b15391286c, content=<a href='/topic/show?id=6bce3e7106' target=_blank style='color:#2F92EE;'>#BTK#</a>, objectTitle=BTK抑制剂tolebrutinib治疗多发性硬化症 (MS) ，显示出“有希望”的结果, objectType=article, longId=218566, objectId=6499218566f3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6499218566f3, replyNumber=0, likeNumber=41, createdTime=2021-10-16, rootId=0, userName=fengting7, userId=61d813108447, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6499218566f3, moduleTitle=BTK抑制剂tolebrutinib治疗多发性硬化症 (MS) ，显示出“有希望”的结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6499218566f3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539127, encodeId=b67f153912e67, content=<a href='/topic/show?id=6bce3e7106' target=_blank style='color:#2F92EE;'>#BTK#</a>, objectTitle=Clin Cancer Res：国产BTK抑制剂泽布替尼治疗难治/复发性Waldenström巨球蛋白血症的疗效和安全性, objectType=article, longId=216579, objectId=57b22165e959, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=57b22165e959, replyNumber=0, likeNumber=36, createdTime=2021-09-03, rootId=0, userName=fengting7, userId=61d813108447, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=57b22165e959, moduleTitle=Clin Cancer Res：国产BTK抑制剂泽布替尼治疗难治/复发性Waldenström巨球蛋白血症的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=57b22165e959)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539126, encodeId=ab7b153912690, content=<a href='/topic/show?id=6bce3e7106' target=_blank style='color:#2F92EE;'>#BTK#</a>, objectTitle=Clin Cancer Res：BTK抑制剂Zanubrutinib治疗复发/难治性Waldenströms巨球蛋白血症(WM)的疗效, objectType=article, longId=214279, objectId=44752142e9a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=44752142e9a0, replyNumber=0, likeNumber=40, createdTime=2021-07-17, rootId=0, userName=fengting7, userId=61d813108447, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=44752142e9a0, moduleTitle=Clin Cancer Res：BTK抑制剂Zanubrutinib治疗复发/难治性Waldenströms巨球蛋白血症(WM)的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=44752142e9a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539125, encodeId=47f015391254f, content=<a href='/topic/show?id=6bce3e7106' target=_blank style='color:#2F92EE;'>#BTK#</a>, objectTitle=Blood：Umbralisib用于BTK或PI3Kδ抑制剂不耐受的CLL患者的疗效和耐受性, objectType=article, longId=204131, objectId=bf81204131cf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bf81204131cf, replyNumber=0, likeNumber=28, createdTime=2020-12-06, rootId=0, userName=fengting7, userId=61d813108447, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bf81204131cf, moduleTitle=Blood：Umbralisib用于BTK或PI3Kδ抑制剂不耐受的CLL患者的疗效和耐受性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bf81204131cf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539124, encodeId=f4fd1539124a4, content=<a href='/topic/show?id=6bce3e7106' target=_blank style='color:#2F92EE;'>#BTK#</a>, objectTitle=Blood：Umbralisib治疗对不能耐受BTK和PI3Kδ抑制剂的CLL安全有效, objectType=article, longId=204085, objectId=2cde204085b1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2cde204085b1, replyNumber=0, likeNumber=27, createdTime=2020-12-05, rootId=0, userName=fengting7, userId=61d813108447, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2cde204085b1, moduleTitle=Blood：Umbralisib治疗对不能耐受BTK和PI3Kδ抑制剂的CLL安全有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2cde204085b1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539123, encodeId=e88c153912312, content=<a href='/topic/show?id=6bce3e7106' target=_blank style='color:#2F92EE;'>#BTK#</a>, objectTitle=BTK抑制剂Rilzabrutinib治疗免疫性血小板减少症：被授予FDA快速通道指定, objectType=article, longId=203551, objectId=920d203551ad, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=920d203551ad, replyNumber=0, likeNumber=34, createdTime=2020-11-21, rootId=0, userName=fengting7, userId=61d813108447, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=920d203551ad, moduleTitle=BTK抑制剂Rilzabrutinib治疗免疫性血小板减少症：被授予FDA快速通道指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=920d203551ad)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539122, encodeId=b774153912221, content=<a href='/topic/show?id=6bce3e7106' target=_blank style='color:#2F92EE;'>#BTK#</a>, objectTitle=BTK抑制剂Calquence降低了COVID-19患者体内炎症，但未能改善生存率, objectType=article, longId=203337, objectId=625b20333ea4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=625b20333ea4, replyNumber=0, likeNumber=44, createdTime=2020-11-15, rootId=0, userName=fengting7, userId=61d813108447, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=625b20333ea4, moduleTitle=BTK抑制剂Calquence降低了COVID-19患者体内炎症，但未能改善生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=625b20333ea4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539121, encodeId=f57c153912142, content=<a href='/topic/show?id=6bce3e7106' target=_blank style='color:#2F92EE;'>#BTK#</a>, objectTitle=阿斯利康的BTK抑制剂Calquence：欧洲获批治疗慢性淋巴细胞白血病, objectType=article, longId=203214, objectId=c984203214b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c984203214b8, replyNumber=0, likeNumber=41, createdTime=2020-11-11, rootId=0, userName=fengting7, userId=61d813108447, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c984203214b8, moduleTitle=阿斯利康的BTK抑制剂Calquence：欧洲获批治疗慢性淋巴细胞白血病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c984203214b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539120, encodeId=f039153912006, content=<a href='/topic/show?id=6bce3e7106' target=_blank style='color:#2F92EE;'>#BTK#</a>, objectTitle=TCT 2020｜王盛教授点评：应用替西罗莫司药物的外膜递送系统为BTK的治疗提供新思路, objectType=article, longId=203002, objectId=53832030020b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=53832030020b, replyNumber=0, likeNumber=34, createdTime=2020-11-08, rootId=0, userName=fengting7, userId=61d813108447, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=53832030020b, moduleTitle=TCT 2020｜王盛教授点评：应用替西罗莫司药物的外膜递送系统为BTK的治疗提供新思路, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=53832030020b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539119, encodeId=991f153911956, content=<a href='/topic/show?id=6bce3e7106' target=_blank style='color:#2F92EE;'>#BTK#</a>, objectTitle=Acta Neuropathologica：BTK的抑制对炎症性中枢神经系统脱髓鞘病中致病性B细胞进展的影响, objectType=article, longId=199079, objectId=eb231990e923, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eb231990e923, replyNumber=0, likeNumber=38, createdTime=2020-08-11, rootId=0, userName=fengting7, userId=61d813108447, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eb231990e923, moduleTitle=Acta Neuropathologica：BTK的抑制对炎症性中枢神经系统脱髓鞘病中致病性B细胞进展的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eb231990e923)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539118, encodeId=e5661539118b4, content=<a href='/topic/show?id=6bce3e7106' target=_blank style='color:#2F92EE;'>#BTK#</a>, objectTitle=Blood：3期试验：两组BTK抑制剂治疗华氏巨球蛋白血症！, objectType=article, longId=198977, objectId=96891989e774, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=96891989e774, replyNumber=0, likeNumber=34, createdTime=2020-08-09, rootId=0, userName=fengting7, userId=61d813108447, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=96891989e774, moduleTitle=Blood：3期试验：两组BTK抑制剂治疗华氏巨球蛋白血症！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=96891989e774)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539117, encodeId=e808153911e9e, content=<a href='/topic/show?id=6bce3e7106' target=_blank style='color:#2F92EE;'>#BTK#</a>, objectTitle=Blood：BTK抑制剂泽布替尼治疗华氏巨球蛋白血症的疗效, objectType=article, longId=198725, objectId=5d63198e2565, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5d63198e2565, replyNumber=0, likeNumber=36, createdTime=2020-08-06, rootId=0, userName=fengting7, userId=61d813108447, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5d63198e2565, moduleTitle=Blood：BTK抑制剂泽布替尼治疗华氏巨球蛋白血症的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5d63198e2565)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539116, encodeId=7852153911628, content=<a href='/topic/show?id=6bce3e7106' target=_blank style='color:#2F92EE;'>#BTK#</a>, objectTitle=Clin Cancer Res：CLL患者停用维奈克拉后，还可从BTK抑制中获益, objectType=article, longId=198662, objectId=82cc19866200, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=82cc19866200, replyNumber=0, likeNumber=0, createdTime=2020-08-05, rootId=0, userName=fengting7, userId=61d813108447, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=82cc19866200, moduleTitle=Clin Cancer Res：CLL患者停用维奈克拉后，还可从BTK抑制中获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=82cc19866200)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539115, encodeId=043a153911526, content=<a href='/topic/show?id=6bce3e7106' target=_blank style='color:#2F92EE;'>#BTK#</a>, objectTitle=Clini Cancer Research：新型BTK抑制剂Zanubrutinib治疗复发性/难治性MCL, objectType=article, longId=197074, objectId=2ffd19e07469, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2ffd19e07469, replyNumber=0, likeNumber=29, createdTime=2020-07-06, rootId=0, userName=fengting7, userId=61d813108447, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2ffd19e07469, moduleTitle=Clini Cancer Research：新型BTK抑制剂Zanubrutinib治疗复发性/难治性MCL, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2ffd19e07469)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539114, encodeId=3a0d1539114df, content=<a href='/topic/show?id=6bce3e7106' target=_blank style='color:#2F92EE;'>#BTK#</a>, objectTitle=Bcl-2联合BTK抑制剂治疗慢性淋巴细胞淋巴瘤, objectType=article, longId=196296, objectId=7b82196296b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7b82196296b4, replyNumber=0, likeNumber=45, createdTime=2020-06-24, rootId=0, userName=fengting7, userId=61d813108447, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7b82196296b4, moduleTitle=Bcl-2联合BTK抑制剂治疗慢性淋巴细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7b82196296b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539113, encodeId=23f815391132f, content=<a href='/topic/show?id=6bce3e7106' target=_blank style='color:#2F92EE;'>#BTK#</a>, objectTitle=百济神州的BTK抑制剂Brukinsa，在欧洲接受审查用于治疗华氏巨球蛋白血症, objectType=article, longId=196197, objectId=35d019619e84, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=35d019619e84, replyNumber=0, likeNumber=37, createdTime=2020-06-22, rootId=0, userName=fengting7, userId=61d813108447, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=35d019619e84, moduleTitle=百济神州的BTK抑制剂Brukinsa，在欧洲接受审查用于治疗华氏巨球蛋白血症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=35d019619e84)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#慢性淋巴细胞白血病# #BTK# #依鲁替尼# #NX-2127#

2024-02-26发表于上海

fengting7 (审核中...)

前往app查看评论内容

#BTK#

BJD：天疱疮治疗新靶点：BTK抑制剂

2022-02-08

fengting7 (审核中...)

前往app查看评论内容

#BTK#

Clin Cancer Res：采用新型BTK抑制剂Zanubrutinib治疗复发/难治性边缘区淋巴瘤

2021-12-08

fengting7 (审核中...)

前往app查看评论内容

#BTK#

Lancet Neurol：口服脑穿透性BTK抑制剂托莱布替尼治疗复发性多发性硬化症的安全性和有效性？

2021-10-25

fengting7 (审核中...)

前往app查看评论内容

#BTK#

BTK抑制剂tolebrutinib治疗多发性硬化症 (MS) ，显示出“有希望”的结果

2021-10-16

fengting7 (审核中...)

前往app查看评论内容

#BTK#

Clin Cancer Res：国产BTK抑制剂泽布替尼治疗难治/复发性Waldenström巨球蛋白血症的疗效和安全性

2021-09-03

fengting7 (审核中...)

前往app查看评论内容

#BTK#

Clin Cancer Res：BTK抑制剂Zanubrutinib治疗复发/难治性Waldenströms巨球蛋白血症(WM)的疗效

2021-07-17

fengting7 (审核中...)

前往app查看评论内容

#BTK#

Blood：Umbralisib用于BTK或PI3Kδ抑制剂不耐受的CLL患者的疗效和耐受性

2020-12-06

fengting7 (审核中...)

前往app查看评论内容

#BTK#

Blood：Umbralisib治疗对不能耐受BTK和PI3Kδ抑制剂的CLL安全有效

2020-12-05

fengting7 (审核中...)

前往app查看评论内容

#BTK#

BTK抑制剂Rilzabrutinib治疗免疫性血小板减少症：被授予FDA快速通道指定

2020-11-21

fengting7 (审核中...)

前往app查看评论内容

#BTK#

BTK抑制剂Calquence降低了COVID-19患者体内炎症，但未能改善生存率

2020-11-15

fengting7 (审核中...)

前往app查看评论内容

#BTK#

阿斯利康的BTK抑制剂Calquence：欧洲获批治疗慢性淋巴细胞白血病

2020-11-11

fengting7 (审核中...)

前往app查看评论内容

#BTK#

TCT 2020｜王盛教授点评：应用替西罗莫司药物的外膜递送系统为BTK的治疗提供新思路

2020-11-08

fengting7 (审核中...)

前往app查看评论内容

#BTK#

Acta Neuropathologica：BTK的抑制对炎症性中枢神经系统脱髓鞘病中致病性B细胞进展的影响

2020-08-11

fengting7 (审核中...)

前往app查看评论内容

#BTK#

Blood：3期试验：两组BTK抑制剂治疗华氏巨球蛋白血症！

2020-08-09

fengting7 (审核中...)

前往app查看评论内容

#BTK#

Blood：BTK抑制剂泽布替尼治疗华氏巨球蛋白血症的疗效

2020-08-06

fengting7 (审核中...)

前往app查看评论内容

#BTK#

Clin Cancer Res：CLL患者停用维奈克拉后，还可从BTK抑制中获益

2020-08-05

fengting7 (审核中...)

前往app查看评论内容

#BTK#

Clini Cancer Research：新型BTK抑制剂Zanubrutinib治疗复发性/难治性MCL

2020-07-06

fengting7 (审核中...)

前往app查看评论内容

#BTK#

Bcl-2联合BTK抑制剂治疗慢性淋巴细胞淋巴瘤

2020-06-24

fengting7 (审核中...)

前往app查看评论内容

#BTK#

百济神州的BTK抑制剂Brukinsa，在欧洲接受审查用于治疗华氏巨球蛋白血症

2020-06-22

科室
- - 订阅+
  - 更多科室
工具
服务